Using machine learning to predict individual patient toxicities from cancer treatments.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 23 11 2021
accepted: 16 05 2022
pubmed: 26 5 2022
medline: 20 8 2022
entrez: 25 5 2022
Statut: ppublish

Résumé

Machine learning (ML) is a powerful tool for interrogating datasets and learning relationships between multiple variables. We utilized a ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomotor symptoms (VMS). A gradient boosted decision model utilizing cross-sectional survey data from 360 EBC patients was created. Seventeen patient- and treatment-specific variables were considered in the model. The outcome variable was based on the Hot Flush Night Sweats (HFNS) Problem Rating Score, and individual scores were dichotomized around the median to indicate individuals with high and low problem scores. Model accuracy was assessed using the area under the receiver operating curve, and conditional partial dependence plots were constructed to illustrate relationships between variables and the outcome of interest. The model area under the ROC curve was 0.731 (SD 0.074). The most important variables in the model were as follows: the number of hot flashes per week, age, the prescription, or use of drug interventions to manage VMS, whether patients were asked about VMS in routine follow-up visits, and the presence or absence of changes to breast cancer treatments due to VMS. A threshold of 17 hot flashes per week was identified as being more predictive of severe VMS. Patients between the ages of 49 and 63 were more likely to report severe symptoms. Machine learning is a unique tool for predicting severe VMS. The use of ML to assess other treatment-related toxicities and their management requires further study.

Identifiants

pubmed: 35614153
doi: 10.1007/s00520-022-07156-6
pii: 10.1007/s00520-022-07156-6
pmc: PMC9385785
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7397-7406

Informations de copyright

© 2022. The Author(s).

Références

Cancer Med. 2020 Feb;9(4):1419-1429
pubmed: 31893575
Breast Cancer Res Treat. 2021 Jun;187(2):427-435
pubmed: 33575860
Br J Clin Psychol. 1995 Nov;34(4):589-99
pubmed: 8563666
J Psychosom Obstet Gynaecol. 2017 Dec;38(4):276-283
pubmed: 28762873
Technol Health Care. 2016;24(1):31-42
pubmed: 26409558
BMC Bioinformatics. 2013 Apr 05;14:119
pubmed: 23560875
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Breast. 2016 Jun;27:116-21
pubmed: 27065357
CA Cancer J Clin. 2016 Jan-Feb;66(1):43-73
pubmed: 26641959
Breast Cancer Res Treat. 2021 Jul;188(2):343-350
pubmed: 34159473
Asian Pac J Cancer Prev. 2018 Jul 27;19(7):1747-1752
pubmed: 30049182
BMC Bioinformatics. 2010 Feb 27;11:110
pubmed: 20187966
Support Care Cancer. 2022 May;30(5):4437-4446
pubmed: 35112212
Br J Cancer. 2008 Dec 2;99(11):1763-8
pubmed: 18985046
J Clin Oncol. 2007 Jan 20;25(3):308-12
pubmed: 17146104
Breast Cancer Res Treat. 2007;105 Suppl 1:45-53
pubmed: 17912635
Proc Int Conf Mach Learn. 2012 Dec 1;2012:349
pubmed: 24350304
J Clin Oncol. 2010 Sep 20;28(27):4120-8
pubmed: 20585090
N Engl J Med. 2014 Jul 10;371(2):107-18
pubmed: 24881463
Int J Med Inform. 2017 Dec;108:1-8
pubmed: 29132615
Climacteric. 2015;18(4):536-44
pubmed: 25748168
N Engl J Med. 2001 Jan 25;344(4):276-85
pubmed: 11172156
Climacteric. 2013 Apr;16(2):235-9
pubmed: 22809134
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Lancet. 2005 Jan 1-7;365(9453):60-2
pubmed: 15639680
BMC Bioinformatics. 2007 Jan 25;8:25
pubmed: 17254353
J Am Coll Surg. 2008 Jan;206(1):66-75
pubmed: 18155570
Menopause. 2018 Mar;25(3):265-272
pubmed: 28968303
JCO Clin Cancer Inform. 2020 Oct;4:885-894
pubmed: 33058693
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 26936232
Oncol Nurs Forum. 2020 Jul 1;47(4):E86-E106
pubmed: 32555553
Lancet Oncol. 2012 Mar;13(3):309-18
pubmed: 22340966
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Acad Pathol. 2019 Sep 03;6:2374289519873088
pubmed: 31523704
Med Phys. 2018 Jul;45(7):3449-3459
pubmed: 29763967

Auteurs

Katherine Marie Cole (KM)

Department of Medicine, Division of Medical Oncology, The University of Ottawa, Ottawa, Canada.

Mark Clemons (M)

Department of Medicine, Division of Medical Oncology, The University of Ottawa, Ottawa, Canada.
Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Sharon McGee (S)

Department of Medicine, Division of Medical Oncology, The University of Ottawa, Ottawa, Canada.

Mashari Alzahrani (M)

Department of Medicine, Division of Medical Oncology, The University of Ottawa, Ottawa, Canada.

Gail Larocque (G)

The Ottawa Hospital Cancer Centre, Ottawa, Canada.

Fiona MacDonald (F)

The Ottawa Hospital Cancer Centre, Ottawa, Canada.

Michelle Liu (M)

Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Gregory R Pond (GR)

Department of Oncology, McMaster University, Hamilton, ON, Canada.

Lucy Mosquera (L)

CHEO Research Institute, University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada.

Lisa Vandermeer (L)

Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Brian Hutton (B)

Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Ardelle Piper (A)

University of Ottawa Health Services, Ottawa, ON, Canada.

Ricardo Fernandes (R)

Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.

Khaled El Emam (KE)

CHEO Research Institute, University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada. kelemam@cheo.on.ca.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada. kelemam@cheo.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH